The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending the oral treatment rimegepant as a cost effective option for acute treatment of migraine in adults.1
Draft guidance published on 14 September recommends rimegepant (also called Vydura and made by Pfizer) for adults who have tried at least two triptans—a group of medicines used for treating migraine or headache—but found that they did not work well enough.
NICE said that around 13 000 …